The Groundbreaking Answer to When did the FDA approve Veozah?
•
3 min read
On May 12, 2023, the U.S. Food and Drug Administration (FDA) approved Veozah (fezolinetant) as a new prescription medication. This landmark decision provided a non-hormonal treatment option for women experiencing moderate to severe vasomotor symptoms (VMS), also known as hot flashes, due to menopause.
